Can-Fite Biopharma Ltd ADR [AMEX: CANF] price plunged by -20.10 percent to reach at -$0.4.
The one-year CANF stock forecast points to a potential upside of 88.64. The average equity rating for CANF stock is currently 1.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on Can-Fite Biopharma Ltd ADR [CANF]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CANF shares is $14.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CANF stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Can-Fite Biopharma Ltd ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 11, 2017. While these analysts kept the previous recommendation, ROTH Capital raised their target price to Buy. The new note on the price target was released on October 19, 2016, representing the official price target for Can-Fite Biopharma Ltd ADR stock. Previously, the target price had yet another raise to $6, while Rodman & Renshaw analysts kept a Buy rating on CANF stock. On November 30, 2015, analysts increased their price target for CANF shares from 4 to 6.
The Average True Range (ATR) for Can-Fite Biopharma Ltd ADR is set at 0.24, with the Price to Sales ratio for CANF stock in the period of the last 12 months amounting to 16.24. The Price to Book ratio for the last quarter was 1.15, with the Price to Cash per share for the same quarter was set at 1.18.
CANF Stock Performance Analysis:
Can-Fite Biopharma Ltd ADR [CANF] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -22.44. With this latest performance, CANF shares dropped by -26.05% in over the last four-week period, additionally sinking by -38.13% over the last 6 months – not to mention a drop of -31.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CANF stock in for the last two-week period is set at 28.74, with the RSI for the last a single of trading hit 23.69, and the three-weeks RSI is set at 32.87 for Can-Fite Biopharma Ltd ADR [CANF]. The present Moving Average for the last 50 days of trading for this stock 2.2083, while it was recorded at 2.0100 for the last single week of trading, and 2.4043 for the last 200 days.
Insight into Can-Fite Biopharma Ltd ADR Fundamentals:
Can-Fite Biopharma Ltd ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.90 and a Current Ratio set at 4.90.
CANF Stock EPS
With the latest financial reports released by the company, Can-Fite Biopharma Ltd ADR posted 0/share EPS, while the average EPS was predicted by analysts to be reported at -1.9/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 1.9. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CANF.
